Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis

作者：Huixian Chen, Yongjing Wang, Chunchun Shao, Chenxi Sun, Chengyun Zheng · 发表于：Hematology · 年份：2021 · DOI：10.1080/16078454.2021.2009648 · 被引用次数：4 · 研究领域：Multiple Myeloma Research and Treatments、Peptidase Inhibition and Analysis、Protein Degradation and Inhibitors

Objectives Multiple myeloma(MM) is a malignant plasma cell disease. Maintenance treatment is beneficial to prolong survival time in patients with MM. Ixazomib was approved for the treatment of relapsed or refractory MM in combination with lenalidomide and dexamethasone. Here, we carried out a meta-analysis to determine the efficacy and safety of ixazomib maintenance therapy.Methods Several databases were searched including PubMed, Web of Science, Embase, the Cochrane Library, etc. The last search dated back to July, 2020. Three clinical trials with a total of 1440 participants with newly diagnosed MM were included.Results and conclusion The pooled HR of progression-free survival (PFS) was 0.69 (95% CI = 0.59–0.79), which suggested ixazomib maintenance therapy could prolong PFS remarkably. In addition, ixazomib was effective in deepening remission (RR = 1.57, 95% CI = 1.26–1.96). But it could not significantly prolong PFS in cytogenetic high-risk patients (HR = 0.74, 95% CI = 0.47–1.00). In terms of adverse reactions, our analysis revealed higher incidences of grade 3–4 thrombocytopenia (RR = 7.47, 95% CI = 2.06–27.06), neuropathy (RR = 1.48, 95% CI = 1.14–1.92), grade 3–4 infections (RR = 1.77, 95% CI = 1.21–2.59) and gastrointestinal disorders (RR = 1.48, 95% CI = 1.32–1.66). There was no significant correlation between the use of ixazomib and grade 3–4 neutropenia (RR = 1.46, 95% CI = 0.77–2.78, p = 0.25) or the occurrence of new primary malignant tumor (RR = 0.88, 95% CI =...